AB Science announces that masitinib study in primary and secondary progressive forms of multiple sclerosis has passed its non-futility test at 2 years The study has completed patient recruitment ...
Long-term follow-up shows all patients who demonstrated sustained disability improvement (SDI) maintained it at all subsequent timepoints 50 percent of patients in the two highest dose Cohorts (3 and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback